SI1441714T1 - Kombinacije, ki obsegajo selektivni inhibitor ciklooksigenaze-2 - Google Patents
Kombinacije, ki obsegajo selektivni inhibitor ciklooksigenaze-2Info
- Publication number
- SI1441714T1 SI1441714T1 SI200230672T SI200230672T SI1441714T1 SI 1441714 T1 SI1441714 T1 SI 1441714T1 SI 200230672 T SI200230672 T SI 200230672T SI 200230672 T SI200230672 T SI 200230672T SI 1441714 T1 SI1441714 T1 SI 1441714T1
- Authority
- SI
- Slovenia
- Prior art keywords
- inhibitor
- combinations
- growth factor
- factor receptor
- receptor tyrosine
- Prior art date
Links
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008472 epithelial growth Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34473401P | 2001-10-25 | 2001-10-25 | |
| US34473501P | 2001-10-25 | 2001-10-25 | |
| US33603301P | 2001-11-15 | 2001-11-15 | |
| PCT/EP2002/011924 WO2003035047A2 (en) | 2001-10-25 | 2002-10-24 | Combinations comprising a selective cyclooxygenase-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1441714T1 true SI1441714T1 (sl) | 2008-06-30 |
Family
ID=27407094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230672T SI1441714T1 (sl) | 2001-10-25 | 2002-10-24 | Kombinacije, ki obsegajo selektivni inhibitor ciklooksigenaze-2 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050043409A1 (sl) |
| EP (1) | EP1441714B1 (sl) |
| JP (1) | JP2005506366A (sl) |
| KR (1) | KR100954625B1 (sl) |
| CN (1) | CN100506224C (sl) |
| AT (1) | ATE381930T1 (sl) |
| AU (2) | AU2006252156A1 (sl) |
| BR (1) | BR0213486A (sl) |
| CA (1) | CA2464309C (sl) |
| CY (1) | CY1108045T1 (sl) |
| DE (1) | DE60224299T2 (sl) |
| DK (1) | DK1441714T3 (sl) |
| ES (1) | ES2295428T3 (sl) |
| HU (1) | HUP0600235A3 (sl) |
| IL (1) | IL161462A0 (sl) |
| MX (1) | MXPA04003878A (sl) |
| NZ (2) | NZ532418A (sl) |
| PL (1) | PL369305A1 (sl) |
| PT (1) | PT1441714E (sl) |
| RU (1) | RU2333754C2 (sl) |
| SI (1) | SI1441714T1 (sl) |
| WO (1) | WO2003035047A2 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| ES2314444T3 (es) | 2003-08-29 | 2009-03-16 | Pfizer Inc. | Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos. |
| CA2537991A1 (en) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
| JP2007505939A (ja) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Ｖｅｇｆ受容体阻害剤と他の治療剤の組み合わせ |
| EA009994B1 (ru) | 2003-12-23 | 2008-06-30 | Пфайзер Инк. | Новые хинолиновые производные |
| JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
| RU2419430C2 (ru) * | 2006-02-09 | 2011-05-27 | Дайити Санкио Компани, Лимитед | Противораковая фармацевтическая композиция |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| WO2013070996A1 (en) | 2011-11-11 | 2013-05-16 | Novartis Ag | Method of treating a proliferative disease |
| MD565Z (ro) * | 2012-05-23 | 2013-07-31 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Procedeu de tratare a seminţelor de sfeclă de zahăr |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308068T3 (es) * | 1996-10-15 | 2008-12-01 | G.D. Searle Llc | Uso de inhibidores de ciclooxigenasa-2 en el tratamiento y la prevencion de neoplasia. |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| NZ333399A (en) * | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
| CA2356929A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| CN1229142C (zh) * | 1999-08-12 | 2005-11-30 | 惠氏控股有限公司 | 用于治疗或抑制结肠息肉和结肠直肠癌的含有nsaid和efgr激酶抑制剂的组合物 |
| HK1052701A1 (zh) * | 1999-12-03 | 2003-09-26 | 辉瑞产品公司 | 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物 |
| ITMI992711A1 (it) * | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
| CA2400197A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| EP1259236A4 (en) * | 2000-02-25 | 2004-11-03 | Merck & Co Inc | Tyrosine kinase inhibitors |
| AU3217501A (en) * | 2000-03-03 | 2001-09-12 | Pfizer Prod Inc | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
-
2002
- 2002-10-24 EP EP02787507A patent/EP1441714B1/en not_active Expired - Lifetime
- 2002-10-24 WO PCT/EP2002/011924 patent/WO2003035047A2/en not_active Ceased
- 2002-10-24 AT AT02787507T patent/ATE381930T1/de active
- 2002-10-24 CA CA2464309A patent/CA2464309C/en not_active Expired - Fee Related
- 2002-10-24 NZ NZ532418A patent/NZ532418A/en not_active IP Right Cessation
- 2002-10-24 PL PL02369305A patent/PL369305A1/xx not_active Application Discontinuation
- 2002-10-24 RU RU2004116069/15A patent/RU2333754C2/ru not_active IP Right Cessation
- 2002-10-24 MX MXPA04003878A patent/MXPA04003878A/es active IP Right Grant
- 2002-10-24 US US10/493,297 patent/US20050043409A1/en not_active Abandoned
- 2002-10-24 DE DE60224299T patent/DE60224299T2/de not_active Expired - Lifetime
- 2002-10-24 BR BR0213486-1A patent/BR0213486A/pt active Search and Examination
- 2002-10-24 PT PT02787507T patent/PT1441714E/pt unknown
- 2002-10-24 IL IL16146202A patent/IL161462A0/xx unknown
- 2002-10-24 ES ES02787507T patent/ES2295428T3/es not_active Expired - Lifetime
- 2002-10-24 DK DK02787507T patent/DK1441714T3/da active
- 2002-10-24 CN CNB028211375A patent/CN100506224C/zh not_active Expired - Fee Related
- 2002-10-24 KR KR1020047006101A patent/KR100954625B1/ko not_active Expired - Fee Related
- 2002-10-24 HU HU0600235A patent/HUP0600235A3/hu unknown
- 2002-10-24 NZ NZ552335A patent/NZ552335A/en not_active IP Right Cessation
- 2002-10-24 SI SI200230672T patent/SI1441714T1/sl unknown
- 2002-10-24 JP JP2003537614A patent/JP2005506366A/ja active Pending
-
2006
- 2006-12-20 AU AU2006252156A patent/AU2006252156A1/en not_active Abandoned
-
2008
- 2008-02-18 CY CY20081100197T patent/CY1108045T1/el unknown
-
2010
- 2010-02-08 AU AU2010200433A patent/AU2010200433A1/en not_active Abandoned
- 2010-11-03 US US12/938,868 patent/US20110046190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0600235A3 (en) | 2008-04-28 |
| CN1575168A (zh) | 2005-02-02 |
| RU2004116069A (ru) | 2005-06-10 |
| ES2295428T3 (es) | 2008-04-16 |
| NZ532418A (en) | 2007-02-23 |
| EP1441714A2 (en) | 2004-08-04 |
| AU2006252156A1 (en) | 2007-01-18 |
| JP2005506366A (ja) | 2005-03-03 |
| BR0213486A (pt) | 2005-05-10 |
| CA2464309A1 (en) | 2003-05-01 |
| US20110046190A1 (en) | 2011-02-24 |
| DE60224299D1 (de) | 2008-02-07 |
| EP1441714B1 (en) | 2007-12-26 |
| HUP0600235A2 (en) | 2007-02-28 |
| CA2464309C (en) | 2012-01-03 |
| AU2010200433A1 (en) | 2010-02-25 |
| DE60224299T2 (de) | 2008-12-11 |
| CN100506224C (zh) | 2009-07-01 |
| KR100954625B1 (ko) | 2010-04-27 |
| CY1108045T1 (el) | 2013-09-04 |
| RU2333754C2 (ru) | 2008-09-20 |
| US20050043409A1 (en) | 2005-02-24 |
| HK1068261A1 (en) | 2005-04-29 |
| WO2003035047A3 (en) | 2003-10-23 |
| ATE381930T1 (de) | 2008-01-15 |
| DK1441714T3 (da) | 2008-03-31 |
| IL161462A0 (en) | 2004-09-27 |
| PT1441714E (pt) | 2008-03-10 |
| MXPA04003878A (es) | 2004-07-08 |
| PL369305A1 (en) | 2005-04-18 |
| NZ552335A (en) | 2008-11-28 |
| WO2003035047A2 (en) | 2003-05-01 |
| KR20040048992A (ko) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL154949A0 (en) | Imidazole derivatives as raf kinase inhibitors | |
| MY169308A (en) | Treatment of tnf? related disorders | |
| GB0121490D0 (en) | Ciompounds | |
| WO2004050026A3 (en) | Compositions and methods for treating prostate cancer | |
| WO2003049702A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| DE60205776D1 (en) | Indolinon-derivative als protein-kinasehemmer | |
| AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
| CY1108045T1 (el) | Συνδυασμοι που περιλαμβανουν εναν επιλεκτο αναστολεα της κυκλοοξυγενασης-2 | |
| AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| WO2001062784A3 (en) | Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer | |
| GB0121494D0 (en) | Compounds | |
| AU3919001A (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| MXPA02001204A (es) | Compuestos calciliticos. | |
| WO2002074756A3 (de) | Urokinase-inhibitoren | |
| IL160382A0 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| BRPI0411126A (pt) | derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| WO2001079505A3 (en) | INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY | |
| AU2002348101A1 (en) | Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer | |
| UA49216A (uk) | Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри | |
| WO2004044226A3 (en) | Induction of cellular senescence by cdk4 disruption for tumor supression and regression | |
| MXPA04002407A (es) | Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer. | |
| UA41034A (uk) | Спосіб лікування хворих із злоякісними пухлинами сечового міхура | |
| AU2013204153A1 (en) | Treatment of TNFalpha related disorders |